|
300 Companies |
|
483 Products |
|
483 Products |
|
198 Mechanisms of Action |
|
25 Trials |
|
7711 News |
|
| «12...3839404142434445464748...156157» |
- decitabine / Generic mfg.
Enrollment change: A Multi-center Study of Low-dose Decitabine for the Treatment of Immune Thrombocytopenia (clinicaltrials.gov) - Apr 22, 2016
P2, N=30, Recruiting, Sponsor: Shandong University
N=60 --> 30
- Trial completion: BOLUS: Comparison of Insulin's Injection Before or After the Meal in Type 1 Diabetic Patients Treated With Insulin Pump (clinicaltrials.gov) - Apr 22, 2016
P3, N=22, Completed, Sponsor: University Hospital, Brest
N=60 --> 30 Recruiting --> Completed
- Trial primary completion date: Long-term Clinical Effectiveness of the Delta Xtend Reverse Total Shoulder (clinicaltrials.gov) - Apr 21, 2016
P=N/A, N=144, Terminated, Sponsor: DePuy International
Recruiting --> Completed Trial primary completion date: Jun 2014 --> Oct 2013
- |||| Tavalisse (fostamatinib) / Rigel
Trial primary completion date: A Efficacy and Safety Study of R935788 in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura (ITP) (clinicaltrials.gov) - Apr 21, 2016
P3, N=75, Active, not recruiting, Sponsor: Rigel Pharmaceuticals
Trial primary completion date: Jun 2014 --> Oct 2013 Trial primary completion date: Mar 2016 --> Jun 2016
- ZB-168 / Zura Bio
Enrollment closed: A Study To Assess The Safety Of PF-06342674 In Adults With Type 1 Diabetes (clinicaltrials.gov) - Apr 21, 2016
P1, N=35, Active, not recruiting, Sponsor: Pfizer
Trial primary completion date: Mar 2016 --> Jun 2016 Recruiting --> Active, not recruiting
- glatiramer acetate / Generic mfg.
Trial completion: Immune Regulation in Multiple Sclerosis: The Effect of Glatiramer Acetate on MicroRNA Expression in Antigen-Presenting Cells (clinicaltrials.gov) - Apr 21, 2016
P=N/A, N=24, Completed, Sponsor: Rutgers, The State University of New Jersey
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- Trial completion, Trial primary completion date: Outpatient Control-to-Range: System and Monitoring Testing (clinicaltrials.gov) - Apr 21, 2016
P=N/A, N=5, Completed, Sponsor: William Sansum Diabetes Center
Active, not recruiting --> Completed Active, not recruiting --> Completed | Trial primary completion date: Dec 2013 --> Dec 2015
- | prezalumab (AMG 557) / Amgen, AstraZeneca
Trial completion: Safety Study of AMG 557 in Subjects With Lupus Arthritis (clinicaltrials.gov) - Apr 21, 2016
P1, N=20, Completed, Sponsor: Amgen
Active, not recruiting --> Completed | Trial primary completion date: Dec 2013 --> Dec 2015 Active, not recruiting --> Completed
- SAR438544 / Sanofi
Trial primary completion date: A Study to Evaluate Safety, Pharmacokinetics, and Pharmacodynamics of a Single Dose of SAR438544 in Comparison to Glucagon in Type 1 Diabetes Mellitus Patients Under Induced Hypoglycemia (clinicaltrials.gov) - Apr 21, 2016
P1, N=44, Not yet recruiting, Sponsor: Sanofi
Active, not recruiting --> Completed Trial primary completion date: Aug 2016 --> Nov 2016
- New trial, Adherence: Check It! Positive Psychology Intervention to Improve Adherence in Adolescents With T1D (clinicaltrials.gov) - Apr 21, 2016
P=N/A, N=120, Completed, Sponsor: Vanderbilt University
- Trial primary completion date: Web-based Support During Pregnancy and Early Motherhood in Women With Type 1 Diabetes (MODIAB-web) (clinicaltrials.gov) - Apr 20, 2016
P=N/A, N=160, Recruiting, Sponsor: G
Trial primary completion date: Aug 2016 --> Nov 2016 Trial primary completion date: Mar 2016 --> Dec 2016
- dexamethasone injection / Generic mfg.
Enrollment change, Trial withdrawal: All-Trans Retinoic Acid (ATRA) Combining Dexamethasone Versus High-dose Dexamethasone for Initial Treatment of Primary Immune Thrombocytopenia (ITP) (clinicaltrials.gov) - Apr 20, 2016
P3, N=0, Withdrawn, Sponsor: Shandong University
Trial primary completion date: Mar 2016 --> Dec 2016 N=80 --> 0 | Recruiting --> Withdrawn
- Enrollment change, Trial withdrawal: The Alteration of Macrophage Function in the Spleen Tissues From Patients With Primary Immune Thrombocytopenia (clinicaltrials.gov) - Apr 20, 2016
P=N/A, N=0, Withdrawn, Sponsor: Shandong University
N=80 --> 0 | Recruiting --> Withdrawn N=20 --> 0 | Recruiting --> Withdrawn
- Promacta (eltrombopag) / Novartis
Enrollment change, Trial withdrawal: Alteration of Different Immune Parameters in Immune Thrombocytopenia ?ITP? Patients Receiving Eltrombopag Treatment (clinicaltrials.gov) - Apr 20, 2016
P=N/A, N=0, Withdrawn, Sponsor: Shandong University
N=20 --> 0 | Recruiting --> Withdrawn N=30 --> 0 | Recruiting --> Withdrawn
- Rituxan (rituximab) / Roche
Enrollment change, Trial withdrawal: Recombinant Human Thrombopoietin (rhTPO) Combining Rituximab Versus High-dose Dexamethasone for Initial Treatment of Primary Immune Thrombocytopenia (ITP) (clinicaltrials.gov) - Apr 20, 2016
P3, N=0, Withdrawn, Sponsor: Shandong University
N=30 --> 0 | Recruiting --> Withdrawn N=240 --> 0 | Recruiting --> Withdrawn
- Rituxan (rituximab) / Roche
Enrollment change, Trial withdrawal: Incritop: Recombinant Human Interleukin-11 Combination Low-dose Rituximab in Immune Thrombocytopenia (clinicaltrials.gov) - Apr 20, 2016
P=N/A, N=0, Withdrawn, Sponsor: Ming Hou
N=240 --> 0 | Recruiting --> Withdrawn N=199 --> 0 | Recruiting --> Withdrawn
- volagidemab (REMD-477) / Amgen, REMD Bio
Enrollment open: Single-dose Study to Evaluate Safety, Tolerability, and Pharmacodynamics of REMD-477 in Subjects With Type 1 Diabetes Mellitus (clinicaltrials.gov) - Apr 20, 2016
P1, N=20, Recruiting, Sponsor: REMD Biotherapeutics, Inc.
N=199 --> 0 | Recruiting --> Withdrawn Not yet recruiting --> Recruiting
- | dexamethasone injection / Generic mfg.
Trial completion, Enrollment change, Trial primary completion date: rhTPO Combining Dexamethasone Versus High-dose Dexamethasone for Initial Treatment of ITP (clinicaltrials.gov) - Apr 20, 2016
P3, N=158, Completed, Sponsor: Shandong University
Not yet recruiting --> Recruiting Recruiting --> Completed | N=200 --> 158 | Trial primary completion date: Jul 2013 --> Jul 2014
- Trial completion, Enrollment change: Autoantibody Specificity and Response to IVIG in ITP (clinicaltrials.gov) - Apr 20, 2016
P=N/A, N=672, Completed, Sponsor: Shandong University
Recruiting --> Completed | N=200 --> 158 | Trial primary completion date: Jul 2013 --> Jul 2014 Recruiting --> Completed | N=200 --> 672
- | Rituxan (rituximab) / Roche
Trial completion, Enrollment change, Trial primary completion date, Combination therapy: rhTPO Combining Rituximab Versus Low-dose Rituximab in Management of ITP (clinicaltrials.gov) - Apr 20, 2016
P3, N=123, Completed, Sponsor: Shandong University
Recruiting --> Completed | N=200 --> 672 Recruiting --> Completed | N=240 --> 123 | Trial primary completion date: Sep 2013 --> Dec 2013
- | Rituxan (rituximab) / Roche
Trial completion, Enrollment change, Trial primary completion date, Combination therapy: Recombinant Human Thrombopoietin in Combination With Rituximab in Immune Thrombocytopenia (ITP) (clinicaltrials.gov) - Apr 20, 2016
P3, N=91, Completed, Sponsor: Ming Hou
Recruiting --> Completed | N=240 --> 123 | Trial primary completion date: Sep 2013 --> Dec 2013 Recruiting --> Completed | N=200 --> 91 | Trial primary completion date: Sep 2012 --> Aug 2013
- dexamethasone / Generic mfg., prednisone / Generic mfg.
Trial completion, Phase classification, Trial primary completion date: GIMEMA: High-dose Dexamethasone Versus Conventional Dose Prednisone for Initial Treatment of Primary Immune Thrombocytopenia (ITP) (clinicaltrials.gov) - Apr 20, 2016
P4, N=261, Completed, Sponsor: Shandong University
Recruiting --> Completed | N=200 --> 91 | Trial primary completion date: Sep 2012 --> Aug 2013 Recruiting --> Completed | Phase classification: PN/A --> P4 | Trial primary completion date: Sep 2012 --> May 2014
- dexamethasone / Generic mfg.
Enrollment change, Trial withdrawal: Different Cycles of High-dose Dexamethasone for Initial Management of Primary Immune Thrombocytopenia (ITP) (clinicaltrials.gov) - Apr 20, 2016
P4, N=0, Withdrawn, Sponsor: Shandong University
Recruiting --> Completed | Phase classification: PN/A --> P4 | Trial primary completion date: Sep 2012 --> May 2014 N=200 --> 0 | Recruiting --> Withdrawn
- cyclosporin A microemulsion / Generic mfg.
Enrollment change, Trial withdrawal: A Multicenter Investigation of Recombinant Human Thrombopoietin (rhTPO) Combining Cyclosporin A Versus Cyclosporin A in Management of Steroid-Resistant/Relapsed Immune Thrombocytopenia ?ITP? (clinicaltrials.gov) - Apr 20, 2016
P3, N=0, Withdrawn, Sponsor: Shandong University
N=200 --> 0 | Recruiting --> Withdrawn N=120 --> 0 | Recruiting --> Withdrawn
- Rituxan (rituximab) / Roche
Enrollment change, Trial withdrawal: A Multicentre Investigation of 2 Cycles Rituximab Compared With Standard Regimen in Management of Steroid-Resistant/Relapsed Immune Thrombocytopenia ?ITP? (clinicaltrials.gov) - Apr 20, 2016
P3, N=0, Withdrawn, Sponsor: Shandong University
N=120 --> 0 | Recruiting --> Withdrawn N=60 --> 0 | Recruiting --> Withdrawn
- dexamethasone / Generic mfg., thalidomide / Generic mfg.
Enrollment change, Trial withdrawal: High-dose Dexamethasone Combining Thalidomide Versus Dexamethasone Mono-therapy for Management of Newly-diagnosed ITP (clinicaltrials.gov) - Apr 20, 2016
P2, N=0, Withdrawn, Sponsor: Shandong University
N=60 --> 0 | Recruiting --> Withdrawn N=240 --> 0 | Recruiting --> Withdrawn
- | dexamethasone / Generic mfg.
Trial completion, Trial initiation date, Trial primary completion date: Caffeic Acid Tablets as a Second-line Therapy for ITP (clinicaltrials.gov) - Apr 20, 2016
P3, N=103, Completed, Sponsor: Shandong University
N=240 --> 0 | Recruiting --> Withdrawn Recruiting --> Completed | Initiation date: Dec 2014 --> Sep 2012 | Trial primary completion date: Mar 2016 --> Dec 2013
- dexamethasone / Generic mfg.
Trial completion: An Investigation of Dexamethasone With Different Doses in the Management of Immune Thrombocytopenia (ITP) (clinicaltrials.gov) - Apr 20, 2016
P2, N=58, Completed, Sponsor: Shandong University
Recruiting --> Completed | Initiation date: Dec 2014 --> Sep 2012 | Trial primary completion date: Mar 2016 --> Dec 2013 Recruiting --> Completed
- Trial completion, Enrollment change: An Investigation of rhTPO With Different Frequencies in the Management of ITP (clinicaltrials.gov) - Apr 20, 2016
P3, N=48, Completed, Sponsor: Shandong University
Recruiting --> Completed Recruiting --> Completed | N=30 --> 48
- |||||||||| AcellBia (rituximab biosimilar) / Biocad, Kocak Farma
New P3 trial: ALTERRA: Clinical Trial to Evaluate Efficacy and Safety of Acellbia (clinicaltrials.gov) - Apr 20, 2016
P3, N=159, Active, not recruiting, Sponsor: Biocad
- |||||||||| Hyrimoz (adalimumab-adaz) / Sandoz
New P3 trial: ADMYRA: Clinical Trial to Compare Treatment With GP2017 and Humira (clinicaltrials.gov) - Apr 20, 2016
P3, N=308, Recruiting, Sponsor: Sandoz
- lansoprazole / Generic mfg., cyclosporine / Generic mfg.
Enrollment change, Trial withdrawal: The Insulin Independence Trial (IIT) Evaluating the Safety and Efficacy of Oral Cyclosporine and Oral Lansoprazole for Insulin Independence Among Patients With Existing Type 1 Diabetes (clinicaltrials.gov) - Apr 19, 2016
P3, N=0, Withdrawn, Sponsor: Perle Bioscience, Inc.
Recruiting --> Completed | N=30 --> 48 N=60 --> 0 | Not yet recruiting --> Withdrawn
- Enrollment closed: Virtual Peer-to-Peer (VP2P) Support Mentoring for Juvenile Idiopathic Arthritis (JIA): A Pilot RCT (clinicaltrials.gov) - Apr 19, 2016
P=N/A, N=40, Active, not recruiting, Sponsor: The Hospital for Sick Children
N=60 --> 0 | Not yet recruiting --> Withdrawn Recruiting --> Active, not recruiting
- Enrollment closed, Trial primary completion date: EDIA: Early Dietary Intervention and Later Signs of Beta-Cell Autoimmunity (clinicaltrials.gov) - Apr 19, 2016
P1, N=120, Active, not recruiting, Sponsor: Helsinki University
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting | Trial primary completion date: Mar 2015 --> Jul 2016
- Trial completion: Assessment of an iPhone Application on Glycemic Control in Type 1 Diabetes (clinicaltrials.gov) - Apr 19, 2016
P=N/A, N=92, Completed, Sponsor: The Hospital for Sick Children
Recruiting --> Active, not recruiting | Trial primary completion date: Mar 2015 --> Jul 2016 Active, not recruiting --> Completed
- Trial primary completion date: Closed-loop Control of Overnight Glucose Levels (Artificial Pancreas) in Type 1 Diab (clinicaltrials.gov) - Apr 19, 2016
P2, N=36, Recruiting, Sponsor: Institut de Recherches Cliniques de Montreal
Active, not recruiting --> Completed Trial primary completion date: Mar 2016 --> Jun 2016
- | Trial completion: Aerobic Exercise and Flu-like Symptoms Following Interferon Beta 1a Injections in Patients With Multiple Sclerosis? (clinicaltrials.gov) - Apr 19, 2016
P=N/A, N=20, Completed, Sponsor: University of Aarhus
Trial primary completion date: Mar 2016 --> Jun 2016 Active, not recruiting --> Completed
- New trial: TWPS: Long-Term Effects of Torso-Weighting (clinicaltrials.gov) - Apr 19, 2016
P=N/A, N=5, Recruiting, Sponsor: San Francisco State University
- omeprazole / Generic mfg., cyclosporine / Generic mfg.
Enrollment change, Trial withdrawal: The Insulin Independence Trial (IIT) Evaluating the Safety and Efficacy of Oral Cyclosporine and Oral Omeprazole for Insulin Independence Among Recent Onset Type 1 Diabetes Patients (clinicaltrials.gov) - Apr 18, 2016
P2b, N=0, Withdrawn, Sponsor: Perle Bioscience, Inc.
Active, not recruiting --> Completed N=81 --> 0 | Not yet recruiting --> Withdrawn
- | intravenous immunoglobulin (IVIG) / Guy's and St Thomas' NHS Foundation Trust
Clinical: STRIVE: A Multicentre randomiSed Controlled TRial of IntraVEnous Immunoglobulin Versus Standard Therapy for Transverse Myelitis (clinicaltrials.gov) - Apr 18, 2016
P3, N=170, Active, not recruiting, Sponsor: Guy's and St Thomas' NHS Foundation Trust
N=81 --> 0 | Not yet recruiting --> Withdrawn Recruiting --> Active, not recruiting
- || Enrollment closed, Enrollment change, Trial primary completion date: BIOFLOW III Asia Registry Orsiro Stent System (clinicaltrials.gov) - Apr 18, 2016
P=N/A, N=364, Active, not recruiting, Sponsor: BIOTRONIK Asia Pacific Pte Ltd
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting | N=880 --> 364 | Trial primary completion date: Sep 2015 --> Apr 2017
- mocravimod (KRP-203) / Priothera
Trial completion, Enrollment change: Safety and Efficacy of KRP203 in Subacute Cutaneous Lupus Erythematosus (clinicaltrials.gov) - Apr 18, 2016
P2, N=10, Completed, Sponsor: Novartis Pharmaceuticals
Recruiting --> Active, not recruiting | N=880 --> 364 | Trial primary completion date: Sep 2015 --> Apr 2017 Terminated --> Completed | N=22 --> 10
- New P1 trial: Safety and Efficacy of Adipose Derived Stem Cells in Refractory Rheumatoid Arthritis, Systemic Lupus Erythematosus or Sharp's Syndrome (clinicaltrials.gov) - Apr 18, 2016
P1, N=20, Recruiting, Sponsor: Arkansas Heart Hospital
- || Zinbryta (daclizumab) / Biogen, AbbVie
Trial primary completion date, Monotherapy: SELECTED: Safety and Efficacy Extension Study of Daclizumab High Yield Process (DAC HYP) (BIIB019) in Participants Who Have Completed Study 205MS202 (NCT00870740) to Treat Relapsing Remitting Multiple Sclerosis (clinicaltrials.gov) - Apr 15, 2016
P2, N=410, Active, not recruiting, Sponsor: Biogen
Terminated --> Completed | N=22 --> 10 Trial primary completion date: Nov 2016 --> Aug 2016
- ||| Trial completion: Study of Electrical Impedance Myography (EIM) in ALS (clinicaltrials.gov) - Apr 15, 2016
P=N/A, N=120, Completed, Sponsor: Skulpt, Inc.
Trial primary completion date: Nov 2016 --> Aug 2016 Active, not recruiting --> Completed
- |||| opicinumab (BIIB033) / Biogen, Avonex (recombinant IFN-?-1a) / Biogen
Trial completion: SYNERGY: Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of BIIB033 in Participants With Relapsing Forms of Multiple Sclerosis When Used Concurrently With Avonex (clinicaltrials.gov) - Apr 15, 2016
P2, N=419, Completed, Sponsor: Biogen
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Trial completion, Enrollment change: Fructose and Glucose and TAS1R2 in Type 1 Diabetes (clinicaltrials.gov) - Apr 15, 2016
P=N/A, N=16, Completed, Sponsor: Universidade Federal do Rio de Janeiro
Active, not recruiting --> Completed Active, not recruiting --> Completed | N=30 --> 16
- | Suglat (ipragliflozin) / EMD Serono, Kotobuki, Astellas
Trial completion: Pharmacodynamics, Pharmacokinetics, and Safety of ASP1941 in Patients With Type 1 Diabetes Mellitus (clinicaltrials.gov) - Apr 15, 2016
P2, N=43, Completed, Sponsor: Astellas Pharma Inc
Active, not recruiting --> Completed | N=30 --> 16 Active, not recruiting --> Completed
- ||||||| dalfampridine / Generic mfg.
Trial completion: ENHANCE: Efficacy and Safety Study of Prolonged-Release Fampridine in Participants With Multiple Sclerosis (clinicaltrials.gov) - Apr 15, 2016
P3, N=646, Completed, Sponsor: Biogen
Active, not recruiting --> Completed Active, not recruiting --> Completed
- ||| Yervoy (ipilimumab) / Ono Pharma, BMS
New trial: Study of Autoimmune Disease Complications Following Ipilimumab Treatment Among Melanoma Patients With Underlying Autoimmune Diseases (clinicaltrials.gov) - Apr 15, 2016
P=N/A, N=370, Active, not recruiting, Sponsor: Bristol-Myers Squibb